KR102800284B1 - Lpa 길항제로서의 시클로헵틸 산 - Google Patents

Info

Publication number

KR102800284B1

KR102800284B1 KR1020217011086A KR20217011086A KR102800284B1 KR 102800284 B1 KR102800284 B1 KR 102800284B1 KR 1020217011086 A KR1020217011086 A KR 1020217011086A KR 20217011086 A KR20217011086 A KR 20217011086A KR 102800284 B1 KR102800284 B1 KR 102800284B1

Authority

KR

South Korea

Prior art keywords

independently

lpa

alkyl

pharmaceutically acceptable

cycloalkyl

Prior art date

2018-09-18

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 239000002253 acid Substances 0.000 title description 33
• 239000005557 antagonist Substances 0.000 title description 31
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 title description 6
• 150000001875 compounds Chemical class 0.000 claims abstract description 248
• 150000003839 salts Chemical class 0.000 claims abstract description 136
• 239000012453 solvate Substances 0.000 claims abstract description 40
• -1 cyano, hydroxyl Chemical group 0.000 claims description 123
• 125000000217 alkyl group Chemical group 0.000 claims description 115
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 92
• 241000124008 Mammalia Species 0.000 claims description 85
• 201000010099 disease Diseases 0.000 claims description 62
• 206010016654 Fibrosis Diseases 0.000 claims description 60
• 230000004761 fibrosis Effects 0.000 claims description 60
• 206010028980 Neoplasm Diseases 0.000 claims description 49
• 229910052739 hydrogen Inorganic materials 0.000 claims description 49
• 125000003545 alkoxy group Chemical group 0.000 claims description 46
• 125000004432 carbon atom Chemical group C* 0.000 claims description 43
• 239000001257 hydrogen Substances 0.000 claims description 41
• 201000011510 cancer Diseases 0.000 claims description 38
• 125000000623 heterocyclic group Chemical group 0.000 claims description 36
• 125000003118 aryl group Chemical group 0.000 claims description 34
• 208000006673 asthma Diseases 0.000 claims description 34
• 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 31
• 208000035475 disorder Diseases 0.000 claims description 29
• 208000005069 pulmonary fibrosis Diseases 0.000 claims description 28
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 26
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 25
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 25
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 24
• 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 24
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 23
• 239000008194 pharmaceutical composition Substances 0.000 claims description 23
• 210000004072 lung Anatomy 0.000 claims description 22
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 22
• 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 20
• 125000001475 halogen functional group Chemical group 0.000 claims description 19
• 125000002947 alkylene group Chemical group 0.000 claims description 18
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 18
• 210000000056 organ Anatomy 0.000 claims description 18
• 125000001072 heteroaryl group Chemical group 0.000 claims description 17
• 208000027866 inflammatory disease Diseases 0.000 claims description 16
• 229910052760 oxygen Inorganic materials 0.000 claims description 16
• 201000002793 renal fibrosis Diseases 0.000 claims description 15
• 206010033128 Ovarian cancer Diseases 0.000 claims description 14
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 14
• 206010039710 Scleroderma Diseases 0.000 claims description 14
• 125000001188 haloalkyl group Chemical group 0.000 claims description 14
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 13
• 125000003282 alkyl amino group Chemical group 0.000 claims description 13
• 210000004556 brain Anatomy 0.000 claims description 13
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 12
• 125000003342 alkenyl group Chemical group 0.000 claims description 12
• 210000003734 kidney Anatomy 0.000 claims description 12
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
• 201000001320 Atherosclerosis Diseases 0.000 claims description 10
• 206010009944 Colon cancer Diseases 0.000 claims description 10
• 125000004452 carbocyclyl group Chemical group 0.000 claims description 10
• 210000003491 skin Anatomy 0.000 claims description 10
• 208000004296 neuralgia Diseases 0.000 claims description 9
• 208000021722 neuropathic pain Diseases 0.000 claims description 9
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
• 206010027476 Metastases Diseases 0.000 claims description 8
• 201000009594 Systemic Scleroderma Diseases 0.000 claims description 8
• 206010042953 Systemic sclerosis Diseases 0.000 claims description 8
• 210000002307 prostate Anatomy 0.000 claims description 8
• 210000001550 testis Anatomy 0.000 claims description 8
• 230000009401 metastasis Effects 0.000 claims description 7
• 210000003205 muscle Anatomy 0.000 claims description 7
• 210000000496 pancreas Anatomy 0.000 claims description 7
• 230000002685 pulmonary effect Effects 0.000 claims description 7
• 125000004076 pyridyl group Chemical group 0.000 claims description 7
• 210000000952 spleen Anatomy 0.000 claims description 7
• 206010060862 Prostate cancer Diseases 0.000 claims description 6
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
• 210000004185 liver Anatomy 0.000 claims description 6
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
• 210000001672 ovary Anatomy 0.000 claims description 6
• 230000001575 pathological effect Effects 0.000 claims description 6
• 210000002784 stomach Anatomy 0.000 claims description 6
• 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 5
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 5
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 5
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
• 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 5
• 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 claims description 5
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
• 230000000747 cardiac effect Effects 0.000 claims description 5
• 210000003169 central nervous system Anatomy 0.000 claims description 5
• 208000020832 chronic kidney disease Diseases 0.000 claims description 5
• 208000029742 colonic neoplasm Diseases 0.000 claims description 5
• 208000033679 diabetic kidney disease Diseases 0.000 claims description 5
• 230000002440 hepatic effect Effects 0.000 claims description 5
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
• 201000001441 melanoma Diseases 0.000 claims description 5
• 125000004043 oxo group Chemical group O=* 0.000 claims description 5
• 201000002528 pancreatic cancer Diseases 0.000 claims description 5
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
• 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 4
• 206010006187 Breast cancer Diseases 0.000 claims description 4
• 208000026310 Breast neoplasm Diseases 0.000 claims description 4
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
• 101710149745 Lysophosphatidic acid receptor 1 Proteins 0.000 claims description 4
• 208000034578 Multiple myelomas Diseases 0.000 claims description 4
• 206010052779 Transplant rejections Diseases 0.000 claims description 4
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
• 210000000813 small intestine Anatomy 0.000 claims description 4
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
• 208000029147 Collagen-vascular disease Diseases 0.000 claims description 3
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
• 208000001132 Osteoporosis Diseases 0.000 claims description 3
• 206010050207 Skin fibrosis Diseases 0.000 claims description 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
• 210000004369 blood Anatomy 0.000 claims description 3
• 239000008280 blood Substances 0.000 claims description 3
• 210000000988 bone and bone Anatomy 0.000 claims description 3
• 210000000481 breast Anatomy 0.000 claims description 3
• 210000001072 colon Anatomy 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 230000008482 dysregulation Effects 0.000 claims description 3
• 210000004696 endometrium Anatomy 0.000 claims description 3
• 210000003128 head Anatomy 0.000 claims description 3
• 201000010536 head and neck cancer Diseases 0.000 claims description 3
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
• 210000000867 larynx Anatomy 0.000 claims description 3
• 208000002780 macular degeneration Diseases 0.000 claims description 3
• 210000001685 thyroid gland Anatomy 0.000 claims description 3
• 206010005949 Bone cancer Diseases 0.000 claims description 2
• 208000018084 Bone neoplasm Diseases 0.000 claims description 2
• 206010058019 Cancer Pain Diseases 0.000 claims description 2
• 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
• 210000003679 cervix uteri Anatomy 0.000 claims description 2
• 210000003238 esophagus Anatomy 0.000 claims description 2
• 210000000232 gallbladder Anatomy 0.000 claims description 2
• 210000004392 genitalia Anatomy 0.000 claims description 2
• 201000002313 intestinal cancer Diseases 0.000 claims description 2
• 210000002429 large intestine Anatomy 0.000 claims description 2
• 210000002200 mouth mucosa Anatomy 0.000 claims description 2
• 210000002850 nasal mucosa Anatomy 0.000 claims description 2
• 210000003739 neck Anatomy 0.000 claims description 2
• 150000002431 hydrogen Chemical class 0.000 claims 12
• 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
• 206010072877 Intestinal fibrosis Diseases 0.000 claims 1
• 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
• 208000033626 Renal failure acute Diseases 0.000 claims 1
• 201000011040 acute kidney failure Diseases 0.000 claims 1
• 239000003085 diluting agent Substances 0.000 claims 1
• 208000005017 glioblastoma Diseases 0.000 claims 1
• 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract description 42
• 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract description 42
• 239000003112 inhibitor Substances 0.000 abstract description 24
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 369
• XGRLSUFHELJJAB-JGSYTFBMSA-M sodium;[(2r)-2-hydroxy-3-[(z)-octadec-9-enoyl]oxypropyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)([O-])=O XGRLSUFHELJJAB-JGSYTFBMSA-M 0.000 description 368
• 238000000034 method Methods 0.000 description 61
• 210000004027 cell Anatomy 0.000 description 60
• 238000011282 treatment Methods 0.000 description 41
• 239000000203 mixture Substances 0.000 description 36
• 230000004913 activation Effects 0.000 description 35
• 102000005962 receptors Human genes 0.000 description 34
• 108020003175 receptors Proteins 0.000 description 34
• 230000001404 mediated effect Effects 0.000 description 33
• 239000003814 drug Substances 0.000 description 29
• 210000002950 fibroblast Anatomy 0.000 description 28
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
• 229910052799 carbon Inorganic materials 0.000 description 26
• 230000015572 biosynthetic process Effects 0.000 description 25
• 230000001965 increasing effect Effects 0.000 description 24
• 238000006243 chemical reaction Methods 0.000 description 23
• 230000014509 gene expression Effects 0.000 description 23
• 125000005843 halogen group Chemical group 0.000 description 23
• 230000001419 dependent effect Effects 0.000 description 22
• 210000001519 tissue Anatomy 0.000 description 22
• 229910052757 nitrogen Inorganic materials 0.000 description 21
• 230000000694 effects Effects 0.000 description 20
• 239000000543 intermediate Substances 0.000 description 20
• 230000035755 proliferation Effects 0.000 description 20
• 239000000243 solution Substances 0.000 description 19
• 229940079593 drug Drugs 0.000 description 18
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
• 125000001424 substituent group Chemical group 0.000 description 17
• 238000003786 synthesis reaction Methods 0.000 description 17
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 16
• 241000699670 Mus sp. Species 0.000 description 16
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 16
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
• 230000011664 signaling Effects 0.000 description 16
• 238000005481 NMR spectroscopy Methods 0.000 description 15
• 150000003852 triazoles Chemical class 0.000 description 15
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
• 125000005842 heteroatom Chemical group 0.000 description 14
• 230000004044 response Effects 0.000 description 14
• 239000003795 chemical substances by application Substances 0.000 description 13
• 230000000875 corresponding effect Effects 0.000 description 13
• 150000002148 esters Chemical class 0.000 description 13
• 235000019439 ethyl acetate Nutrition 0.000 description 13
• 229940002612 prodrug Drugs 0.000 description 13
• 239000000651 prodrug Substances 0.000 description 13
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 12
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 12
• 208000027418 Wounds and injury Diseases 0.000 description 12
• 125000004429 atom Chemical group 0.000 description 12
• 239000002585 base Substances 0.000 description 12
• 150000001721 carbon Chemical group 0.000 description 12
• 238000004519 manufacturing process Methods 0.000 description 12
• 238000013508 migration Methods 0.000 description 12
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
• 230000029663 wound healing Effects 0.000 description 12
• 230000004663 cell proliferation Effects 0.000 description 11
• 230000006378 damage Effects 0.000 description 11
• 238000009472 formulation Methods 0.000 description 11
• 210000002216 heart Anatomy 0.000 description 11
• 230000005012 migration Effects 0.000 description 11
• 125000004433 nitrogen atom Chemical group N* 0.000 description 11
• 230000008506 pathogenesis Effects 0.000 description 11
• 230000037361 pathway Effects 0.000 description 11
• 239000011541 reaction mixture Substances 0.000 description 11
• 208000023504 respiratory system disease Diseases 0.000 description 11
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
• 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 10
• 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 10
• 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 description 10
• 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 description 10
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 10
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 10
• 206010061218 Inflammation Diseases 0.000 description 10
• 208000029523 Interstitial Lung disease Diseases 0.000 description 10
• 208000010668 atopic eczema Diseases 0.000 description 10
• 210000002744 extracellular matrix Anatomy 0.000 description 10
• 230000004054 inflammatory process Effects 0.000 description 10
• 208000014674 injury Diseases 0.000 description 10
• 125000002950 monocyclic group Chemical group 0.000 description 10
• 150000003904 phospholipids Chemical class 0.000 description 10
• 239000000047 product Substances 0.000 description 10
• 239000002904 solvent Substances 0.000 description 10
• 102000004127 Cytokines Human genes 0.000 description 9
• 108090000695 Cytokines Proteins 0.000 description 9
• 102000004890 Interleukin-8 Human genes 0.000 description 9
• 108090001007 Interleukin-8 Proteins 0.000 description 9
• 208000002193 Pain Diseases 0.000 description 9
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 9
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 9
• 239000003153 chemical reaction reagent Substances 0.000 description 9
• 230000008602 contraction Effects 0.000 description 9
• 125000004404 heteroalkyl group Chemical group 0.000 description 9
• 230000005764 inhibitory process Effects 0.000 description 9
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 9
• 229940096397 interleukin-8 Drugs 0.000 description 9
• 150000002632 lipids Chemical class 0.000 description 9
• 208000010125 myocardial infarction Diseases 0.000 description 9
• 230000002206 pro-fibrotic effect Effects 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• 210000002966 serum Anatomy 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• 229910052717 sulfur Inorganic materials 0.000 description 9
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
• 102000030621 adenylate cyclase Human genes 0.000 description 8
• 108060000200 adenylate cyclase Proteins 0.000 description 8
• 108010022198 alkylglycerophosphoethanolamine phosphodiesterase Proteins 0.000 description 8
• 230000000172 allergic effect Effects 0.000 description 8
• 125000004103 aminoalkyl group Chemical group 0.000 description 8
• 230000033115 angiogenesis Effects 0.000 description 8
• 125000003710 aryl alkyl group Chemical group 0.000 description 8
• 239000000460 chlorine Substances 0.000 description 8
• 239000012043 crude product Substances 0.000 description 8
• 238000010511 deprotection reaction Methods 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 210000002919 epithelial cell Anatomy 0.000 description 8
• 229960001340 histamine Drugs 0.000 description 8
• 230000002401 inhibitory effect Effects 0.000 description 8
• 239000002245 particle Substances 0.000 description 8
• 230000008439 repair process Effects 0.000 description 8
• 229920006395 saturated elastomer Polymers 0.000 description 8
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 7
• 208000006011 Stroke Diseases 0.000 description 7
• 102000014384 Type C Phospholipases Human genes 0.000 description 7
• 108010079194 Type C Phospholipases Proteins 0.000 description 7
• 238000009825 accumulation Methods 0.000 description 7
• 239000013543 active substance Substances 0.000 description 7
• 229910052801 chlorine Inorganic materials 0.000 description 7
• 238000011161 development Methods 0.000 description 7
• 229910052731 fluorine Inorganic materials 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 125000004438 haloalkoxy group Chemical group 0.000 description 7
• 238000004128 high performance liquid chromatography Methods 0.000 description 7
• 210000000651 myofibroblast Anatomy 0.000 description 7
• 230000002265 prevention Effects 0.000 description 7
• 230000037390 scarring Effects 0.000 description 7
• 241000894007 species Species 0.000 description 7
• 208000024891 symptom Diseases 0.000 description 7
• 210000001635 urinary tract Anatomy 0.000 description 7
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 6
• 206010003445 Ascites Diseases 0.000 description 6
• 208000024172 Cardiovascular disease Diseases 0.000 description 6
• 102000030782 GTP binding Human genes 0.000 description 6
• 108091000058 GTP-Binding Proteins 0.000 description 6
• BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 6
• 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 6
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 6
• 229910004298 SiO 2 Inorganic materials 0.000 description 6
• 230000002159 abnormal effect Effects 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 125000002619 bicyclic group Chemical group 0.000 description 6
• 230000001275 ca(2+)-mobilization Effects 0.000 description 6
• 230000012292 cell migration Effects 0.000 description 6
• 239000012530 fluid Substances 0.000 description 6
• 230000002496 gastric effect Effects 0.000 description 6
• 229960001476 pentoxifylline Drugs 0.000 description 6
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 6
• 208000002815 pulmonary hypertension Diseases 0.000 description 6
• 230000028327 secretion Effects 0.000 description 6
• 125000001544 thienyl group Chemical group 0.000 description 6
• 210000001541 thymus gland Anatomy 0.000 description 6
• 230000009466 transformation Effects 0.000 description 6
• 230000002792 vascular Effects 0.000 description 6
• 239000003643 water by type Substances 0.000 description 6
• 108010006654 Bleomycin Proteins 0.000 description 5
• 201000004624 Dermatitis Diseases 0.000 description 5
• 206010012438 Dermatitis atopic Diseases 0.000 description 5
• 108091006027 G proteins Proteins 0.000 description 5
• 206010020772 Hypertension Diseases 0.000 description 5
• 102000016994 Lysolipids receptors Human genes 0.000 description 5
• 108091054455 MAP kinase family Proteins 0.000 description 5
• 102000043136 MAP kinase family Human genes 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 241000283973 Oryctolagus cuniculus Species 0.000 description 5
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 5
• 208000004608 Ureteral Obstruction Diseases 0.000 description 5
• 206010052428 Wound Diseases 0.000 description 5
• 125000002252 acyl group Chemical group 0.000 description 5
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 5
• 125000004414 alkyl thio group Chemical group 0.000 description 5
• 150000001412 amines Chemical class 0.000 description 5
• 238000003556 assay Methods 0.000 description 5
• 201000008937 atopic dermatitis Diseases 0.000 description 5
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 5
• 229960001561 bleomycin Drugs 0.000 description 5
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 5
• 229910052794 bromium Inorganic materials 0.000 description 5
• 125000002837 carbocyclic group Chemical group 0.000 description 5
• 229910002091 carbon monoxide Inorganic materials 0.000 description 5
• 230000010261 cell growth Effects 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 230000004069 differentiation Effects 0.000 description 5
• 210000002889 endothelial cell Anatomy 0.000 description 5
• 230000007613 environmental effect Effects 0.000 description 5
• 229910052736 halogen Inorganic materials 0.000 description 5
• 150000002367 halogens Chemical class 0.000 description 5
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 5
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 5
• 125000001041 indolyl group Chemical group 0.000 description 5
• 230000006698 induction Effects 0.000 description 5
• 230000000977 initiatory effect Effects 0.000 description 5
• 208000019423 liver disease Diseases 0.000 description 5
• 125000001624 naphthyl group Chemical group 0.000 description 5
• 125000003367 polycyclic group Chemical group 0.000 description 5
• 108090000623 proteins and genes Proteins 0.000 description 5
• 229940044551 receptor antagonist Drugs 0.000 description 5
• 239000002464 receptor antagonist Substances 0.000 description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 description 5
• 239000011734 sodium Substances 0.000 description 5
• 210000003518 stress fiber Anatomy 0.000 description 5
• 230000004083 survival effect Effects 0.000 description 5
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
• ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 4
• HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 4
• CEKWIWMBGWDIDS-UHFFFAOYSA-N 4-cycloheptyl-2h-triazole Chemical compound C1CCCCCC1C1=CNN=N1 CEKWIWMBGWDIDS-UHFFFAOYSA-N 0.000 description 4
• 108010085238 Actins Proteins 0.000 description 4
• 102000007469 Actins Human genes 0.000 description 4
• 101150071146 COX2 gene Proteins 0.000 description 4
• 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 206010014561 Emphysema Diseases 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• 102100037362 Fibronectin Human genes 0.000 description 4
• 108010067306 Fibronectins Proteins 0.000 description 4
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
• 208000004454 Hyperalgesia Diseases 0.000 description 4
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
• 208000002260 Keloid Diseases 0.000 description 4
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
• 108010027749 Lysophospholipid Receptors Proteins 0.000 description 4
• 108010016731 PPAR gamma Proteins 0.000 description 4
• 101150000187 PTGS2 gene Proteins 0.000 description 4
• 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 4
• 102000015439 Phospholipases Human genes 0.000 description 4
• 108010064785 Phospholipases Proteins 0.000 description 4
• 108010003541 Platelet Activating Factor Proteins 0.000 description 4
• 201000004681 Psoriasis Diseases 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• 208000007536 Thrombosis Diseases 0.000 description 4
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
• 206010047115 Vasculitis Diseases 0.000 description 4
• 206010047139 Vasoconstriction Diseases 0.000 description 4
• 150000007513 acids Chemical class 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 239000012190 activator Substances 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 125000001931 aliphatic group Chemical group 0.000 description 4
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 4
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
• 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 4
• 230000000975 bioactive effect Effects 0.000 description 4
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
• 238000001023 centrifugal evaporation Methods 0.000 description 4
• 206010008118 cerebral infarction Diseases 0.000 description 4
• 208000023819 chronic asthma Diseases 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 238000007796 conventional method Methods 0.000 description 4
• 230000008878 coupling Effects 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 238000005859 coupling reaction Methods 0.000 description 4
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
• 229910052805 deuterium Inorganic materials 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 239000003172 expectorant agent Substances 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 230000003176 fibrotic effect Effects 0.000 description 4
• 125000000524 functional group Chemical group 0.000 description 4
• 125000002541 furyl group Chemical group 0.000 description 4
• 239000003102 growth factor Substances 0.000 description 4
• 208000006454 hepatitis Diseases 0.000 description 4
• 125000002883 imidazolyl group Chemical group 0.000 description 4
• 238000000338 in vitro Methods 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 230000009545 invasion Effects 0.000 description 4
• 125000000842 isoxazolyl group Chemical group 0.000 description 4
• 210000001117 keloid Anatomy 0.000 description 4
• 208000017169 kidney disease Diseases 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 230000002503 metabolic effect Effects 0.000 description 4
• 210000001616 monocyte Anatomy 0.000 description 4
• 210000002241 neurite Anatomy 0.000 description 4
• 125000002971 oxazolyl group Chemical group 0.000 description 4
• 125000004430 oxygen atom Chemical group O* 0.000 description 4
• 208000033808 peripheral neuropathy Diseases 0.000 description 4
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
• 238000002953 preparative HPLC Methods 0.000 description 4
• 230000002062 proliferating effect Effects 0.000 description 4
• 230000001681 protective effect Effects 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 125000003226 pyrazolyl group Chemical group 0.000 description 4
• 230000007115 recruitment Effects 0.000 description 4
• 238000007634 remodeling Methods 0.000 description 4
• DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 4
• 125000004434 sulfur atom Chemical group 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 125000003831 tetrazolyl group Chemical group 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 125000000335 thiazolyl group Chemical group 0.000 description 4
• 125000004306 triazinyl group Chemical group 0.000 description 4
• 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 4
• 230000025033 vasoconstriction Effects 0.000 description 4
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
• FQKFPGMGQXQHLP-UHFFFAOYSA-N 1-hydroxytriazole Chemical compound ON1C=CN=N1 FQKFPGMGQXQHLP-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 206010002329 Aneurysm Diseases 0.000 description 3
• 208000031104 Arterial Occlusive disease Diseases 0.000 description 3
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 3
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
• 206010006458 Bronchitis chronic Diseases 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
• 102000008186 Collagen Human genes 0.000 description 3
• 108010035532 Collagen Proteins 0.000 description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
• 201000003883 Cystic fibrosis Diseases 0.000 description 3
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
• 208000001640 Fibromyalgia Diseases 0.000 description 3
• 206010018364 Glomerulonephritis Diseases 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 3
• 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 3
• 208000019693 Lung disease Diseases 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
• 241000872931 Myoporum sandwicense Species 0.000 description 3
• 150000001204 N-oxides Chemical class 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 108010089484 PRM-151 Proteins 0.000 description 3
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 3
• 108091008611 Protein Kinase B Proteins 0.000 description 3
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 3
• 206010039491 Sarcoma Diseases 0.000 description 3
• 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 3
• 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 3
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
• 208000024770 Thyroid neoplasm Diseases 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 108010016133 acylglycerol kinase Proteins 0.000 description 3
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 230000010085 airway hyperresponsiveness Effects 0.000 description 3
• 208000037883 airway inflammation Diseases 0.000 description 3
• 125000000304 alkynyl group Chemical group 0.000 description 3
• 208000002205 allergic conjunctivitis Diseases 0.000 description 3
• 201000010105 allergic rhinitis Diseases 0.000 description 3
• 125000003368 amide group Chemical group 0.000 description 3
• 239000002870 angiogenesis inducing agent Substances 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 230000003510 anti-fibrotic effect Effects 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• 208000021328 arterial occlusion Diseases 0.000 description 3
• 125000004104 aryloxy group Chemical group 0.000 description 3
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
• 125000005605 benzo group Chemical group 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 230000036772 blood pressure Effects 0.000 description 3
• 206010006451 bronchitis Diseases 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 230000036755 cellular response Effects 0.000 description 3
• 230000035605 chemotaxis Effects 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 208000007451 chronic bronchitis Diseases 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 229920001436 collagen Polymers 0.000 description 3
• 239000003246 corticosteroid Substances 0.000 description 3
• WZCRDVTWUYLPTR-UHFFFAOYSA-N cyclohept-2-en-1-one Chemical compound O=C1CCCCC=C1 WZCRDVTWUYLPTR-UHFFFAOYSA-N 0.000 description 3
• NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000007783 downstream signaling Effects 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
• 150000004665 fatty acids Chemical class 0.000 description 3
• 230000035876 healing Effects 0.000 description 3
• 210000003630 histaminocyte Anatomy 0.000 description 3
• 150000002430 hydrocarbons Chemical group 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 230000001969 hypertrophic effect Effects 0.000 description 3
• 230000000642 iatrogenic effect Effects 0.000 description 3
• 125000002632 imidazolidinyl group Chemical group 0.000 description 3
• 208000026278 immune system disease Diseases 0.000 description 3
• 229960003444 immunosuppressant agent Drugs 0.000 description 3
• 239000003018 immunosuppressive agent Substances 0.000 description 3
• 210000000936 intestine Anatomy 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 229940043355 kinase inhibitor Drugs 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 206010025135 lupus erythematosus Diseases 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 125000002757 morpholinyl group Chemical group 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 201000005962 mycosis fungoides Diseases 0.000 description 3
• 208000031225 myocardial ischemia Diseases 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 229960004378 nintedanib Drugs 0.000 description 3
• XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 125000001715 oxadiazolyl group Chemical group 0.000 description 3
• 125000000160 oxazolidinyl group Chemical group 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 210000001428 peripheral nervous system Anatomy 0.000 description 3
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
• 230000001766 physiological effect Effects 0.000 description 3
• 229960005095 pioglitazone Drugs 0.000 description 3
• ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 3
• 229960003073 pirfenidone Drugs 0.000 description 3
• 239000011591 potassium Substances 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 125000006239 protecting group Chemical group 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 125000003373 pyrazinyl group Chemical group 0.000 description 3
• 125000000714 pyrimidinyl group Chemical group 0.000 description 3
• 125000000168 pyrrolyl group Chemical group 0.000 description 3
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 238000006722 reduction reaction Methods 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 208000037803 restenosis Diseases 0.000 description 3
• 239000011435 rock Substances 0.000 description 3
• 229960004586 rosiglitazone Drugs 0.000 description 3
• 201000000306 sarcoidosis Diseases 0.000 description 3
• 230000003248 secreting effect Effects 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 210000002027 skeletal muscle Anatomy 0.000 description 3
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 208000020431 spinal cord injury Diseases 0.000 description 3
• 210000000273 spinal nerve root Anatomy 0.000 description 3
• 239000011593 sulfur Substances 0.000 description 3
• 238000004808 supercritical fluid chromatography Methods 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
• CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 201000002510 thyroid cancer Diseases 0.000 description 3
• 229910052723 transition metal Inorganic materials 0.000 description 3
• 150000003624 transition metals Chemical class 0.000 description 3
• 125000001425 triazolyl group Chemical group 0.000 description 3
• 210000003932 urinary bladder Anatomy 0.000 description 3
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
• OUPXSLGGCPUZJJ-SARDKLJWSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-n-[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfonyl-1-oxobutan-2-y Chemical compound C([C@@H](C(=O)N(C)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCS(C)(=O)=O)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 OUPXSLGGCPUZJJ-SARDKLJWSA-N 0.000 description 2
• NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 2
• SHKXZIQNFMOPBS-OOMQYRRCSA-N (4r)-4-[(3s,5s,7r,8r,9s,10s,12s,13r,14s,17r)-7,12-dihydroxy-3-(icosanoylamino)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound O[C@H]1C[C@@H]2[C@@]3(C)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC)C[C@H]3C[C@@H](O)[C@H]2[C@@H]2CC[C@H]([C@H](C)CCC(O)=O)[C@]21C SHKXZIQNFMOPBS-OOMQYRRCSA-N 0.000 description 2
• 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 2
• PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
• RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 2
• 125000005955 1H-indazolyl group Chemical group 0.000 description 2
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
• NSKJTUFFDRENDM-ZVGUSBNCSA-N 2-aminoethanethiol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound NCCS.OC(=O)[C@H](O)[C@@H](O)C(O)=O NSKJTUFFDRENDM-ZVGUSBNCSA-N 0.000 description 2
• SUHZEOGKWHFVCI-UHFFFAOYSA-N 3-ethenylcycloheptan-1-ol Chemical compound C(=C)C1CC(CCCC1)O SUHZEOGKWHFVCI-UHFFFAOYSA-N 0.000 description 2
• BMMWZBBMGBYUTJ-UHFFFAOYSA-N 3-ethenylcycloheptan-1-one Chemical compound C=CC1CCCCC(=O)C1 BMMWZBBMGBYUTJ-UHFFFAOYSA-N 0.000 description 2
• WDBNGXLHMZSUEI-UHFFFAOYSA-N 5-[1'-(1-cyclopropyl-4-methoxy-3-methylindole-6-carbonyl)-4-oxospiro[3h-chromene-2,4'-piperidine]-6-yl]pyridine-3-carboxylic acid Chemical compound C1=C(C)C=2C(OC)=CC(C(=O)N3CCC4(CC3)OC3=CC=C(C=C3C(=O)C4)C=3C=C(C=NC=3)C(O)=O)=CC=2N1C1CC1 WDBNGXLHMZSUEI-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 208000036065 Airway Remodeling Diseases 0.000 description 2
• 206010001881 Alveolar proteinosis Diseases 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• 206010054793 Arterial fibrosis Diseases 0.000 description 2
• 206010003210 Arteriosclerosis Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
• 206010004146 Basal cell carcinoma Diseases 0.000 description 2
• 201000006474 Brain Ischemia Diseases 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 206010048962 Brain oedema Diseases 0.000 description 2
• 208000011691 Burkitt lymphomas Diseases 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• 208000005623 Carcinogenesis Diseases 0.000 description 2
• 201000009030 Carcinoma Diseases 0.000 description 2
• 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
• 206010008120 Cerebral ischaemia Diseases 0.000 description 2
• 229940122444 Chemokine receptor antagonist Drugs 0.000 description 2
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
• 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
• 208000016192 Demyelinating disease Diseases 0.000 description 2
• 206010012305 Demyelination Diseases 0.000 description 2
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
• 206010013774 Dry eye Diseases 0.000 description 2
• 208000001708 Dupuytren contracture Diseases 0.000 description 2
• 206010014967 Ependymoma Diseases 0.000 description 2
• 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 2
• 208000012468 Ewing sarcoma/peripheral primitive neuroectodermal tumor Diseases 0.000 description 2
• 206010063560 Excessive granulation tissue Diseases 0.000 description 2
• 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
• 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 description 2
• 208000018522 Gastrointestinal disease Diseases 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 206010018691 Granuloma Diseases 0.000 description 2
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
• 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 2
• 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
• 208000018565 Hemochromatosis Diseases 0.000 description 2
• 241000711549 Hepacivirus C Species 0.000 description 2
• 208000006933 Hermanski-Pudlak Syndrome Diseases 0.000 description 2
• 206010071775 Hermansky-Pudlak syndrome Diseases 0.000 description 2
• 208000017604 Hodgkin disease Diseases 0.000 description 2
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
• 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 2
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
• 206010021263 IgA nephropathy Diseases 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 108010002616 Interleukin-5 Proteins 0.000 description 2
• 208000005615 Interstitial Cystitis Diseases 0.000 description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 description 2
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 2
• 206010067125 Liver injury Diseases 0.000 description 2
• 208000004852 Lung Injury Diseases 0.000 description 2
• 206010049459 Lymphangioleiomyomatosis Diseases 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 208000019695 Migraine disease Diseases 0.000 description 2
• UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 208000003445 Mouth Neoplasms Diseases 0.000 description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
• 208000012902 Nervous system disease Diseases 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• 208000009905 Neurofibromatoses Diseases 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• 206010029888 Obliterative bronchiolitis Diseases 0.000 description 2
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 2
• 206010061328 Ovarian epithelial cancer Diseases 0.000 description 2
• 108091007960 PI3Ks Proteins 0.000 description 2
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
• 208000016222 Pancreatic disease Diseases 0.000 description 2
• 208000018737 Parkinson disease Diseases 0.000 description 2
• 208000004362 Penile Induration Diseases 0.000 description 2
• 208000020758 Peyronie disease Diseases 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 206010035600 Pleural fibrosis Diseases 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
• 108090000315 Protein Kinase C Proteins 0.000 description 2
• 102000003923 Protein Kinase C Human genes 0.000 description 2
• 102100037314 Protein kinase C gamma type Human genes 0.000 description 2
• 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 201000000582 Retinoblastoma Diseases 0.000 description 2
• 206010038934 Retinopathy proliferative Diseases 0.000 description 2
• 206010039085 Rhinitis allergic Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 241001303601 Rosacea Species 0.000 description 2
• 108060006706 SRC Proteins 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
• 108700025832 Serum Response Element Proteins 0.000 description 2
• 201000010001 Silicosis Diseases 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• 206010041067 Small cell lung cancer Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
• KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
• 206010069363 Traumatic lung injury Diseases 0.000 description 2
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
• 208000024780 Urticaria Diseases 0.000 description 2
• 208000032594 Vascular Remodeling Diseases 0.000 description 2
• 229930003427 Vitamin E Natural products 0.000 description 2
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
• YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 2
• 229960004308 acetylcysteine Drugs 0.000 description 2
• 208000033017 acquired idiopathic inflammatory myopathy Diseases 0.000 description 2
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
• 239000000048 adrenergic agonist Substances 0.000 description 2
• 210000001552 airway epithelial cell Anatomy 0.000 description 2
• NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
• BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 2
• 125000004450 alkenylene group Chemical group 0.000 description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
• 150000003973 alkyl amines Chemical class 0.000 description 2
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
• 125000004419 alkynylene group Chemical group 0.000 description 2
• 239000013566 allergen Substances 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 238000005576 amination reaction Methods 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 229940035676 analgesics Drugs 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 230000000954 anitussive effect Effects 0.000 description 2
• 239000000730 antalgic agent Substances 0.000 description 2
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 2
• 230000002924 anti-infective effect Effects 0.000 description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 description 2
• 239000002260 anti-inflammatory agent Substances 0.000 description 2
• 238000009175 antibody therapy Methods 0.000 description 2
• 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
• 239000003146 anticoagulant agent Substances 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 229940125715 antihistaminic agent Drugs 0.000 description 2
• 239000000739 antihistaminic agent Substances 0.000 description 2
• 229960005475 antiinfective agent Drugs 0.000 description 2
• 239000003434 antitussive agent Substances 0.000 description 2
• 229940124584 antitussives Drugs 0.000 description 2
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
• 208000011775 arteriosclerosis disease Diseases 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
• 125000004658 aryl carbonyl amino group Chemical group 0.000 description 2
• 125000005129 aryl carbonyl group Chemical group 0.000 description 2
• 125000005135 aryl sulfinyl group Chemical group 0.000 description 2
• 125000005110 aryl thio group Chemical group 0.000 description 2
• 239000010425 asbestos Substances 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 208000024998 atopic conjunctivitis Diseases 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• 230000003305 autocrine Effects 0.000 description 2
• 125000002393 azetidinyl group Chemical group 0.000 description 2
• 150000001540 azides Chemical class 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 2
• 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 2
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
• 125000005512 benztetrazolyl group Chemical group 0.000 description 2
• 210000000013 bile duct Anatomy 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 230000008512 biological response Effects 0.000 description 2
• 239000000090 biomarker Substances 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 208000006752 brain edema Diseases 0.000 description 2
• 239000012267 brine Substances 0.000 description 2
• 201000003848 bronchiolitis obliterans Diseases 0.000 description 2
• 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 2
• 229940124630 bronchodilator Drugs 0.000 description 2
• 239000000168 bronchodilator agent Substances 0.000 description 2
• 230000036952 cancer formation Effects 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
• 125000005884 carbocyclylalkyl group Chemical group 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
• 231100000504 carcinogenesis Toxicity 0.000 description 2
• 210000001054 cardiac fibroblast Anatomy 0.000 description 2
• 230000009787 cardiac fibrosis Effects 0.000 description 2
• 229950000771 carlumab Drugs 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 230000005754 cellular signaling Effects 0.000 description 2
• 208000015114 central nervous system disease Diseases 0.000 description 2
• 208000026106 cerebrovascular disease Diseases 0.000 description 2
• IBGLGMOPHJQDJB-IHRRRGAJSA-N chembl1950289 Chemical compound C1C[C@@H](O)CC[C@@H]1NC1=NC=C(N=C(NC=2C(=CC(F)=CC=2F)F)N2[C@@H]3COCC3)C2=N1 IBGLGMOPHJQDJB-IHRRRGAJSA-N 0.000 description 2
• CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 2
• 239000002559 chemokine receptor antagonist Substances 0.000 description 2
• 239000000812 cholinergic antagonist Substances 0.000 description 2
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 230000006020 chronic inflammation Effects 0.000 description 2
• 229950001653 cilomilast Drugs 0.000 description 2
• 230000007882 cirrhosis Effects 0.000 description 2
• 208000010877 cognitive disease Diseases 0.000 description 2
• 230000037319 collagen production Effects 0.000 description 2
• 239000003636 conditioned culture medium Substances 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 229960001334 corticosteroids Drugs 0.000 description 2
• 238000006880 cross-coupling reaction Methods 0.000 description 2
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 238000006352 cycloaddition reaction Methods 0.000 description 2
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
• RXQDTMKIWOTJSQ-UHFFFAOYSA-N cycloheptyloxycycloheptane Chemical compound C1CCCCCC1OC1CCCCCC1 RXQDTMKIWOTJSQ-UHFFFAOYSA-N 0.000 description 2
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• 201000003146 cystitis Diseases 0.000 description 2
• 230000016396 cytokine production Effects 0.000 description 2
• NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
• 239000000850 decongestant Substances 0.000 description 2
• 229940124581 decongestants Drugs 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 210000004443 dendritic cell Anatomy 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
• 229960003957 dexamethasone Drugs 0.000 description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 206010013990 dysuria Diseases 0.000 description 2
• 210000003979 eosinophil Anatomy 0.000 description 2
• SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 2
• 230000003419 expectorant effect Effects 0.000 description 2
• 229940066493 expectorants Drugs 0.000 description 2
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
• 210000001508 eye Anatomy 0.000 description 2
• 239000003889 eye drop Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 230000019305 fibroblast migration Effects 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 229960002714 fluticasone Drugs 0.000 description 2
• MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 2
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 2
• 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 2
• 229950004003 fresolimumab Drugs 0.000 description 2
• IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 2
• 229960004675 fusidic acid Drugs 0.000 description 2
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• AFLFKFHDSCQHOL-IZZDOVSWSA-N gft505 Chemical compound C1=CC(SC)=CC=C1C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 AFLFKFHDSCQHOL-IZZDOVSWSA-N 0.000 description 2
• 210000001126 granulation tissue Anatomy 0.000 description 2
• 201000009277 hairy cell leukemia Diseases 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 125000005553 heteroaryloxy group Chemical group 0.000 description 2
• 125000004415 heterocyclylalkyl group Chemical group 0.000 description 2
• 230000004047 hyperresponsiveness Effects 0.000 description 2
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
• 208000013643 idiopathic inflammatory myopathy Diseases 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 239000005414 inactive ingredient Substances 0.000 description 2
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 102000006495 integrins Human genes 0.000 description 2
• 108010044426 integrins Proteins 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
• 125000001786 isothiazolyl group Chemical group 0.000 description 2
• 210000002510 keratinocyte Anatomy 0.000 description 2
• 238000011813 knockout mouse model Methods 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 108010074060 lecithinized superoxide dismutase Proteins 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 2
• 239000003199 leukotriene receptor blocking agent Substances 0.000 description 2
• 150000002617 leukotrienes Chemical class 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 229960003088 loratadine Drugs 0.000 description 2
• JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 231100000515 lung injury Toxicity 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 159000000003 magnesium salts Chemical class 0.000 description 2
• RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 229950010572 mercaptamine bitartrate Drugs 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
• 229960003105 metformin Drugs 0.000 description 2
• 229960000668 metreleptin Drugs 0.000 description 2
• 108700008455 metreleptin Proteins 0.000 description 2
• 229960005127 montelukast Drugs 0.000 description 2
• 230000000510 mucolytic effect Effects 0.000 description 2
• 229940066491 mucolytics Drugs 0.000 description 2
• 229960003816 muromonab-cd3 Drugs 0.000 description 2
• 206010028537 myelofibrosis Diseases 0.000 description 2
• 210000003098 myoblast Anatomy 0.000 description 2
• 230000002107 myocardial effect Effects 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 2
• 239000007922 nasal spray Substances 0.000 description 2
• 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 201000004931 neurofibromatosis Diseases 0.000 description 2
• 230000004766 neurogenesis Effects 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
• ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 2
• 229960001601 obeticholic acid Drugs 0.000 description 2
• 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
• CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 description 2
• 229950008687 oltipraz Drugs 0.000 description 2
• 229960000470 omalizumab Drugs 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 2
• 239000005022 packaging material Substances 0.000 description 2
• 208000024691 pancreas disease Diseases 0.000 description 2
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
• 239000003358 phospholipase A2 inhibitor Substances 0.000 description 2
• XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 2
• 229960005330 pimecrolimus Drugs 0.000 description 2
• 125000004193 piperazinyl group Chemical group 0.000 description 2
• 125000003386 piperidinyl group Chemical group 0.000 description 2
• 210000002826 placenta Anatomy 0.000 description 2
• 230000007505 plaque formation Effects 0.000 description 2
• 230000010118 platelet activation Effects 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 230000009862 primary prevention Effects 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
• TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 2
• BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 2
• BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 2
• 235000018102 proteins Nutrition 0.000 description 2
• 230000001696 purinergic effect Effects 0.000 description 2
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
• 125000002098 pyridazinyl group Chemical group 0.000 description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 238000004007 reversed phase HPLC Methods 0.000 description 2
• 229910052895 riebeckite Inorganic materials 0.000 description 2
• 238000006798 ring closing metathesis reaction Methods 0.000 description 2
• 125000006413 ring segment Chemical group 0.000 description 2
• 201000004700 rosacea Diseases 0.000 description 2
• 229960002052 salbutamol Drugs 0.000 description 2
• 229960004017 salmeterol Drugs 0.000 description 2
• 231100000241 scar Toxicity 0.000 description 2
• 210000004116 schwann cell Anatomy 0.000 description 2
• 230000009863 secondary prevention Effects 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 229950009513 simtuzumab Drugs 0.000 description 2
• 208000000587 small cell lung carcinoma Diseases 0.000 description 2
• 210000002460 smooth muscle Anatomy 0.000 description 2
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
• JLVSPVFPBBFMBE-HXSWCURESA-N sphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP([O-])(=O)OCC[N+](C)(C)C JLVSPVFPBBFMBE-HXSWCURESA-N 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 150000003456 sulfonamides Chemical class 0.000 description 2
• 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 229960001967 tacrolimus Drugs 0.000 description 2
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
• 229950002902 tanzisertib Drugs 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
• 229960003433 thalidomide Drugs 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 125000001113 thiadiazolyl group Chemical group 0.000 description 2
• 230000008719 thickening Effects 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• 150000003573 thiols Chemical class 0.000 description 2
• 208000008732 thymoma Diseases 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 230000009772 tissue formation Effects 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 229950000835 tralokinumab Drugs 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000000844 transformation Methods 0.000 description 2
• 230000007704 transition Effects 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
• 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
• 210000003556 vascular endothelial cell Anatomy 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• 235000019165 vitamin E Nutrition 0.000 description 2
• 229940046009 vitamin E Drugs 0.000 description 2
• 239000011709 vitamin E Substances 0.000 description 2
• 230000037314 wound repair Effects 0.000 description 2
• 229960004764 zafirlukast Drugs 0.000 description 2
• MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 2
• 229960005332 zileuton Drugs 0.000 description 2
• XMKZGJIOOIIRGQ-RTBURBONSA-N (1R,3R)-3-[6-[5-[[cyclobutylmethyl(methyl)carbamoyl]oxymethyl]-1-methyltriazol-4-yl]-2-methylpyridin-3-yl]oxycycloheptane-1-carboxylic acid Chemical compound C1(CCC1)CN(C(=O)OCC1=C(N=NN1C)C1=CC=C(C(=N1)C)O[C@H]1C[C@@H](CCCC1)C(=O)O)C XMKZGJIOOIIRGQ-RTBURBONSA-N 0.000 description 1
• XMKZGJIOOIIRGQ-MOPGFXCFSA-N (1R,3S)-3-[6-[5-[[cyclobutylmethyl(methyl)carbamoyl]oxymethyl]-1-methyltriazol-4-yl]-2-methylpyridin-3-yl]oxycycloheptane-1-carboxylic acid Chemical compound C1C(CN(C)C(=O)OCC=2N(N=NC=2C2=CC=C(O[C@H]3CCCC[C@@H](C(=O)O)C3)C(C)=N2)C)CC1 XMKZGJIOOIIRGQ-MOPGFXCFSA-N 0.000 description 1
• XMKZGJIOOIIRGQ-RBUKOAKNSA-N (1S,3R)-3-[6-[5-[[cyclobutylmethyl(methyl)carbamoyl]oxymethyl]-1-methyltriazol-4-yl]-2-methylpyridin-3-yl]oxycycloheptane-1-carboxylic acid Chemical compound C1C(CN(C)C(=O)OCC=2N(N=NC=2C2=CC=C(O[C@@H]3CCCC[C@@H](C3)C(=O)O)C(C)=N2)C)CC1 XMKZGJIOOIIRGQ-RBUKOAKNSA-N 0.000 description 1
• HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
• LOVPHSMOAVXQIH-UHFFFAOYSA-N (4-nitrophenyl) hydrogen carbonate Chemical compound OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LOVPHSMOAVXQIH-UHFFFAOYSA-N 0.000 description 1
• 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
• 125000006832 (C1-C10) alkylene group Chemical group 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
• 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 1
• WAPNOHKVXSQRPX-SSDOTTSWSA-N (R)-1-phenylethanol Chemical compound C[C@@H](O)C1=CC=CC=C1 WAPNOHKVXSQRPX-SSDOTTSWSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
• OQJBFFCUFALWQL-BUHFOSPRSA-N (ne)-n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)\N=N\C(=O)N1CCCCC1 OQJBFFCUFALWQL-BUHFOSPRSA-N 0.000 description 1
• FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
• 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
• 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
• 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
• 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
• 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
• DFDDLFCSYLTQBP-UHFFFAOYSA-N 1-cyclobutyl-n-methylmethanamine Chemical compound CNCC1CCC1 DFDDLFCSYLTQBP-UHFFFAOYSA-N 0.000 description 1
• 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• 125000006017 1-propenyl group Chemical group 0.000 description 1
• QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
• QLSWIGRIBOSFMV-UHFFFAOYSA-N 1h-pyrrol-2-amine Chemical compound NC1=CC=CN1 QLSWIGRIBOSFMV-UHFFFAOYSA-N 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
• HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• 101710186725 2-acylglycerol O-acyltransferase 2 Proteins 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000006040 2-hexenyl group Chemical group 0.000 description 1
• 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
• VLUPBAFHRLPJTN-UHFFFAOYSA-N 2-methyl-6-[1-methyl-5-(oxan-2-yloxymethyl)triazol-4-yl]pyridin-3-ol Chemical compound CC1=NC(=CC=C1O)C=1N=NN(C=1COC1OCCCC1)C VLUPBAFHRLPJTN-UHFFFAOYSA-N 0.000 description 1
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
• 125000006024 2-pentenyl group Chemical group 0.000 description 1
• KRTGJZMJJVEKRX-UHFFFAOYSA-N 2-phenylethan-1-yl Chemical group [CH2]CC1=CC=CC=C1 KRTGJZMJJVEKRX-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• OADYBXHYXPEGHX-UHFFFAOYSA-N 2h-triazol-4-ylmethanol Chemical class OCC1=CNN=N1 OADYBXHYXPEGHX-UHFFFAOYSA-N 0.000 description 1
• KXIRUURHQWYIGN-UHFFFAOYSA-N 3-(3-ethenylcycloheptyl)oxy-2-methyl-6-[1-methyl-5-(oxan-2-yloxymethyl)triazol-4-yl]pyridine Chemical compound CC1=C(C=CC(=N1)C2=C(N(N=N2)C)COC3CCCCO3)OC4CCCCC(C4)C=C KXIRUURHQWYIGN-UHFFFAOYSA-N 0.000 description 1
• QKWWPNYUWNZRID-QHGAOEGBSA-N 3-[2-methyl-6-[1-methyl-5-[[(1R)-1-phenylethoxy]carbonylamino]triazol-4-yl]pyridin-3-yl]oxycycloheptane-1-carboxylic acid Chemical compound [C@H](OC(=O)NC=1N(N=NC=1C1=CC=C(OC2CC(CCCC2)C(=O)O)C(C)=N1)C)(C1=CC=CC=C1)C QKWWPNYUWNZRID-QHGAOEGBSA-N 0.000 description 1
• CMXYCCYYLPFFDO-UHFFFAOYSA-N 3-[6-[5-[(6-ethylpyrimidin-4-yl)oxymethyl]-1-methyltriazol-4-yl]-2-methylpyridin-3-yl]oxycycloheptane-1-carboxylic acid Chemical compound C(C)C1=CC(=NC=N1)OCC1=C(N=NN1C)C1=CC=C(C(=N1)C)OC1CC(CCCC1)C(=O)O CMXYCCYYLPFFDO-UHFFFAOYSA-N 0.000 description 1
• CXKDVHKKYGQPRG-UHFFFAOYSA-N 3-[6-[5-[[benzyl(methyl)carbamoyl]oxymethyl]-1-methyltriazol-4-yl]-2-methylpyridin-3-yl]oxycycloheptane-1-carboxylic acid Chemical compound C1=C(CN(C(=O)OCC=2N(N=NC=2C2=CC=C(OC3CC(CCCC3)C(=O)O)C(C)=N2)C)C)C=CC=C1 CXKDVHKKYGQPRG-UHFFFAOYSA-N 0.000 description 1
• 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
• 125000006041 3-hexenyl group Chemical group 0.000 description 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• MFZPGDQOHZBCRW-UHFFFAOYSA-N 4-chloro-6-ethylpyrimidine Chemical compound CCC1=CC(Cl)=NC=N1 MFZPGDQOHZBCRW-UHFFFAOYSA-N 0.000 description 1
• 125000006042 4-hexenyl group Chemical group 0.000 description 1
• 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
• 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
• JOOFLCZWUXFSTP-UHFFFAOYSA-N 5-[5-(3-methoxycarbonylcycloheptyl)oxy-6-methylpyridin-2-yl]-3-methyltriazole-4-carboxylic acid Chemical compound N=1N(C(=C(N=1)C1=CC=C(OC2CC(CCCC2)C(=O)OC)C(C)=N1)C(=O)O)C JOOFLCZWUXFSTP-UHFFFAOYSA-N 0.000 description 1
• 125000006043 5-hexenyl group Chemical group 0.000 description 1
• 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
• 125000005330 8 membered heterocyclic group Chemical group 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• 206010000050 Abdominal adhesions Diseases 0.000 description 1
• 108010043137 Actomyosin Proteins 0.000 description 1
• 108700016155 Acyl transferases Proteins 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 102100024296 Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 1
• 208000035939 Alveolitis allergic Diseases 0.000 description 1
• 206010061424 Anal cancer Diseases 0.000 description 1
• 208000033309 Analgesic asthma syndrome Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 208000003120 Angiofibroma Diseases 0.000 description 1
• 208000007860 Anus Neoplasms Diseases 0.000 description 1
• 206010073360 Appendix cancer Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 200000000007 Arterial disease Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 206010003557 Asthma exercise induced Diseases 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
• 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 206010005042 Bladder fibrosis Diseases 0.000 description 1
• 206010006143 Brain stem glioma Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
• XMKZGJIOOIIRGQ-OALUTQOASA-N C1C(CN(C)C(=O)OCC=2N(N=NC=2C2=CC=C(O[C@H]3CCCC[C@@H](C3)C(=O)O)C(C)=N2)C)CC1 Chemical compound C1C(CN(C)C(=O)OCC=2N(N=NC=2C2=CC=C(O[C@H]3CCCC[C@@H](C3)C(=O)O)C(C)=N2)C)CC1 XMKZGJIOOIIRGQ-OALUTQOASA-N 0.000 description 1
• 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
• 229940124638 COX inhibitor Drugs 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 208000020446 Cardiac disease Diseases 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 102000011068 Cdc42 Human genes 0.000 description 1
• 108050001278 Cdc42 Proteins 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 102100025051 Cell division control protein 42 homolog Human genes 0.000 description 1
• 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
• 229930186147 Cephalosporin Natural products 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 208000000094 Chronic Pain Diseases 0.000 description 1
• 241000193155 Clostridium botulinum Species 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 208000027932 Collagen disease Diseases 0.000 description 1
• 206010010726 Conjunctival oedema Diseases 0.000 description 1
• 102000010970 Connexin Human genes 0.000 description 1
• 108050001175 Connexin Proteins 0.000 description 1
• 206010010996 Corneal degeneration Diseases 0.000 description 1
• 208000028006 Corneal injury Diseases 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
• 206010012441 Dermatitis bullous Diseases 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 240000001879 Digitalis lutea Species 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 206010063045 Effusion Diseases 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 102100030013 Endoribonuclease Human genes 0.000 description 1
• 101710199605 Endoribonuclease Proteins 0.000 description 1
• 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
• 206010014824 Endotoxic shock Diseases 0.000 description 1
• 108020002908 Epoxide hydrolase Proteins 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
• 229940124783 FAK inhibitor Drugs 0.000 description 1
• 108010000196 Factor XIIIa Proteins 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
• 208000027445 Farmer Lung Diseases 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
• 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 1
• 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 1
• 102100040134 Free fatty acid receptor 4 Human genes 0.000 description 1
• 108091007911 GSKs Proteins 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 208000021309 Germ cell tumor Diseases 0.000 description 1
• 208000006334 Gingival Fibromatosis Diseases 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
• 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 102100038367 Gremlin-1 Human genes 0.000 description 1
• 101710169781 Gremlin-1 Proteins 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• IVDFJHOHABJVEH-UHFFFAOYSA-N HOCMe2CMe2OH Natural products CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 208000004196 Heart Aneurysm Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 206010019668 Hepatic fibrosis Diseases 0.000 description 1
• 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 101000890672 Homo sapiens Free fatty acid receptor 4 Proteins 0.000 description 1
• 101001038001 Homo sapiens Lysophosphatidic acid receptor 2 Proteins 0.000 description 1
• 101001038006 Homo sapiens Lysophosphatidic acid receptor 3 Proteins 0.000 description 1
• 101001038043 Homo sapiens Lysophosphatidic acid receptor 4 Proteins 0.000 description 1
• 101001038037 Homo sapiens Lysophosphatidic acid receptor 5 Proteins 0.000 description 1
• 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 1
• 101000864393 Homo sapiens Protein BUD31 homolog Proteins 0.000 description 1
• 101001026864 Homo sapiens Protein kinase C gamma type Proteins 0.000 description 1
• 101001092910 Homo sapiens Serum amyloid P-component Proteins 0.000 description 1
• 208000035154 Hyperesthesia Diseases 0.000 description 1
• 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
• 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
• 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
• 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
• 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
• 206010061252 Intraocular melanoma Diseases 0.000 description 1
• 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
• 208000011200 Kawasaki disease Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 206010023421 Kidney fibrosis Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
• 102000007330 LDL Lipoproteins Human genes 0.000 description 1
• 108010007622 LDL Lipoproteins Proteins 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• 102100025357 Lipid-phosphate phosphatase Human genes 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 108070000013 Lysolipids receptors Proteins 0.000 description 1
• 102100040387 Lysophosphatidic acid receptor 2 Human genes 0.000 description 1
• 102100040388 Lysophosphatidic acid receptor 3 Human genes 0.000 description 1
• 102100040405 Lysophosphatidic acid receptor 4 Human genes 0.000 description 1
• 102100040404 Lysophosphatidic acid receptor 5 Human genes 0.000 description 1
• 108020002496 Lysophospholipase Proteins 0.000 description 1
• 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 1
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
• 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 1
• 208000032271 Malignant tumor of penis Diseases 0.000 description 1
• 102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 244000062730 Melissa officinalis Species 0.000 description 1
• 235000010654 Melissa officinalis Nutrition 0.000 description 1
• 206010027406 Mesothelioma Diseases 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 206010027603 Migraine headaches Diseases 0.000 description 1
• 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
• 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 1
• 238000006751 Mitsunobu reaction Methods 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 102100035971 Molybdopterin molybdenumtransferase Human genes 0.000 description 1
• 101710119577 Molybdopterin molybdenumtransferase Proteins 0.000 description 1
• 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 1
• 101000966781 Mus musculus Lysophosphatidic acid receptor 1 Proteins 0.000 description 1
• 102000016349 Myosin Light Chains Human genes 0.000 description 1
• 108010067385 Myosin Light Chains Proteins 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• 108010082699 NADPH Oxidase 4 Proteins 0.000 description 1
• 102100021872 NADPH oxidase 4 Human genes 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 101150071357 NPP2 gene Proteins 0.000 description 1
• 206010028748 Nasal obstruction Diseases 0.000 description 1
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
• 206010029279 Neurogenic bladder Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 208000022873 Ocular disease Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 206010053159 Organ failure Diseases 0.000 description 1
• 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
• 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 102000023984 PPAR alpha Human genes 0.000 description 1
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 206010034299 Penile cancer Diseases 0.000 description 1
• 206010034665 Peritoneal fibrosis Diseases 0.000 description 1
• 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
• 206010034811 Pharyngeal cancer Diseases 0.000 description 1
• 208000016012 Phenotypic abnormality Diseases 0.000 description 1
• 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
• 101100080097 Phytophthora capsici NLP2 gene Proteins 0.000 description 1
• 206010050487 Pinealoblastoma Diseases 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
• 206010035603 Pleural mesothelioma Diseases 0.000 description 1
• 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
• 206010035737 Pneumonia viral Diseases 0.000 description 1
• 206010036018 Pollakiuria Diseases 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 102100030160 Protein BUD31 homolog Human genes 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 102100027384 Proto-oncogene tyrosine-protein kinase Src Human genes 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 206010051739 Pulmonary sepsis Diseases 0.000 description 1
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
• 102100022122 Ras-related C3 botulinum toxin substrate 1 Human genes 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 206010038687 Respiratory distress Diseases 0.000 description 1
• 206010039094 Rhinitis perennial Diseases 0.000 description 1
• 208000036284 Rhinitis seasonal Diseases 0.000 description 1
• 108091006647 SLC9A1 Proteins 0.000 description 1
• 102000001332 SRC Human genes 0.000 description 1
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 208000008765 Sciatica Diseases 0.000 description 1
• 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
• 102100036202 Serum amyloid P-component Human genes 0.000 description 1
• 208000009359 Sezary Syndrome Diseases 0.000 description 1
• 208000021388 Sezary disease Diseases 0.000 description 1
• 206010048676 Sjogren-Larsson Syndrome Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010072170 Skin wound Diseases 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 238000003428 Staudinger Azide reduction reaction Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 208000032450 Surgical Shock Diseases 0.000 description 1
• 230000006043 T cell recruitment Effects 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• 206010043515 Throat cancer Diseases 0.000 description 1
• 201000009365 Thymic carcinoma Diseases 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 206010044541 Traumatic shock Diseases 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
• 206010046431 Urethral cancer Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• 208000012931 Urologic disease Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 102000003848 Uteroglobin Human genes 0.000 description 1
• 108090000203 Uteroglobin Proteins 0.000 description 1
• 201000005969 Uveal melanoma Diseases 0.000 description 1
• 206010046914 Vaginal infection Diseases 0.000 description 1
• 201000008100 Vaginitis Diseases 0.000 description 1
• 229940116211 Vasopressin antagonist Drugs 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical group [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000009798 acute exacerbation Effects 0.000 description 1
• 231100000354 acute hepatitis Toxicity 0.000 description 1
• 206010069351 acute lung injury Diseases 0.000 description 1
• 208000005298 acute pain Diseases 0.000 description 1
• 102000045404 acyltransferase activity proteins Human genes 0.000 description 1
• 108700014220 acyltransferase activity proteins Proteins 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 210000000577 adipose tissue Anatomy 0.000 description 1
• 230000011759 adipose tissue development Effects 0.000 description 1
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
• 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 210000005057 airway smooth muscle cell Anatomy 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910001413 alkali metal ion Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
• 125000005236 alkanoylamino group Chemical group 0.000 description 1
• 150000001345 alkine derivatives Chemical class 0.000 description 1
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
• 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
• 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
• 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
• 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
• 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
• 150000005215 alkyl ethers Chemical class 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 206010053552 allodynia Diseases 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 230000008382 alveolar damage Effects 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 210000004727 amygdala Anatomy 0.000 description 1
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 230000003288 anthiarrhythmic effect Effects 0.000 description 1
• 230000006909 anti-apoptosis Effects 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 239000003416 antiarrhythmic agent Substances 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
• 239000003420 antiserotonin agent Substances 0.000 description 1
• 229960004676 antithrombotic agent Drugs 0.000 description 1
• 201000011165 anus cancer Diseases 0.000 description 1
• 208000007474 aortic aneurysm Diseases 0.000 description 1
• 208000021780 appendiceal neoplasm Diseases 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 229940114079 arachidonic acid Drugs 0.000 description 1
• 235000021342 arachidonic acid Nutrition 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000009697 arginine Nutrition 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 230000006793 arrhythmia Effects 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 125000005018 aryl alkenyl group Chemical group 0.000 description 1
• 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
• 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
• 125000001769 aryl amino group Chemical group 0.000 description 1
• 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
• 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
• 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
• 125000005164 aryl thioalkyl group Chemical group 0.000 description 1
• 210000003567 ascitic fluid Anatomy 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 208000024744 aspirin-induced respiratory disease Diseases 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 230000000923 atherogenic effect Effects 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 230000001746 atrial effect Effects 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
• 230000005549 barrier dysfunction Effects 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
• 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 239000003613 bile acid Substances 0.000 description 1
• 239000012867 bioactive agent Substances 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
• 230000004641 brain development Effects 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 210000000621 bronchi Anatomy 0.000 description 1
• 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 230000001593 cAMP accumulation Effects 0.000 description 1
• 230000003185 calcium uptake Effects 0.000 description 1
• PHDSHKDUDPVVGU-UHFFFAOYSA-N carbamic acid;2h-triazole Chemical compound NC(O)=O.C=1C=NNN=1 PHDSHKDUDPVVGU-UHFFFAOYSA-N 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• 125000004623 carbolinyl group Chemical group 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000004709 cell invasion Effects 0.000 description 1
• 230000009087 cell motility Effects 0.000 description 1
• 229940124587 cephalosporin Drugs 0.000 description 1
• 150000001780 cephalosporins Chemical class 0.000 description 1
• 210000003710 cerebral cortex Anatomy 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 230000031902 chemoattractant activity Effects 0.000 description 1
• 230000002113 chemopreventative effect Effects 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 208000029771 childhood onset asthma Diseases 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
• FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
• 229940106681 chloroacetic acid Drugs 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
• 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000011278 co-treatment Methods 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 201000010989 colorectal carcinoma Diseases 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 230000009989 contractile response Effects 0.000 description 1
• 230000001595 contractor effect Effects 0.000 description 1
• 210000004087 cornea Anatomy 0.000 description 1
• 210000000399 corneal endothelial cell Anatomy 0.000 description 1
• 210000003239 corneal fibroblast Anatomy 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 201000004897 cough variant asthma Diseases 0.000 description 1
• 235000001671 coumarin Nutrition 0.000 description 1
• 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 125000000000 cycloalkoxy group Chemical group 0.000 description 1
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
• 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• XSYZCZPCBXYQTE-UHFFFAOYSA-N cyclodecylcyclodecane Chemical compound C1CCCCCCCCC1C1CCCCCCCCC1 XSYZCZPCBXYQTE-UHFFFAOYSA-N 0.000 description 1
• QCRFMSUKWRQZEM-UHFFFAOYSA-N cycloheptanol Chemical compound OC1CCCCCC1 QCRFMSUKWRQZEM-UHFFFAOYSA-N 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 230000003436 cytoskeletal effect Effects 0.000 description 1
• 210000004292 cytoskeleton Anatomy 0.000 description 1
• 230000020176 deacylation Effects 0.000 description 1
• 238000005947 deacylation reaction Methods 0.000 description 1
• 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000032459 dedifferentiation Effects 0.000 description 1
• 208000018180 degenerative disc disease Diseases 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 210000004207 dermis Anatomy 0.000 description 1
• 238000005828 desilylation reaction Methods 0.000 description 1
• 150000001975 deuterium Chemical group 0.000 description 1
• 125000000950 dibromo group Chemical group Br* 0.000 description 1
• 150000001991 dicarboxylic acids Chemical class 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• 101150042537 dld1 gene Proteins 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 description 1
• 229960002084 dronedarone Drugs 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000009510 drug design Methods 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 239000003221 ear drop Substances 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 239000003602 elastase inhibitor Substances 0.000 description 1
• 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
• 208000014616 embryonal neoplasm Diseases 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 239000002308 endothelin receptor antagonist Substances 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 239000003344 environmental pollutant Substances 0.000 description 1
• 230000009483 enzymatic pathway Effects 0.000 description 1
• 208000010932 epithelial neoplasm Diseases 0.000 description 1
• 229960001208 eplerenone Drugs 0.000 description 1
• JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• UMYZHWLYICNGRQ-UHFFFAOYSA-N ethanol;heptane Chemical compound CCO.CCCCCCC UMYZHWLYICNGRQ-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 210000002388 eustachian tube Anatomy 0.000 description 1
• 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 208000024519 eye neoplasm Diseases 0.000 description 1
• 208000022195 farmer lung disease Diseases 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 239000003527 fibrinolytic agent Substances 0.000 description 1
• 230000003480 fibrinolytic effect Effects 0.000 description 1
• 230000000893 fibroproliferative effect Effects 0.000 description 1
• 239000012065 filter cake Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 125000003709 fluoroalkyl group Chemical group 0.000 description 1
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
• 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 210000005153 frontal cortex Anatomy 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 125000003838 furazanyl group Chemical group 0.000 description 1
• 201000010175 gallbladder cancer Diseases 0.000 description 1
• 210000003976 gap junction Anatomy 0.000 description 1
• 208000017211 gastric neuroendocrine tumor G1 Diseases 0.000 description 1
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 210000001648 gingival epithelial cell Anatomy 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 230000001434 glomerular Effects 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 210000003780 hair follicle Anatomy 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• 125000004994 halo alkoxy alkyl group Chemical group 0.000 description 1
• 125000004992 haloalkylamino group Chemical group 0.000 description 1
• 125000004995 haloalkylthio group Chemical group 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 208000018578 heart valve disease Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 230000023597 hemostasis Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 231100000234 hepatic damage Toxicity 0.000 description 1
• 231100000753 hepatic injury Toxicity 0.000 description 1
• 210000004024 hepatic stellate cell Anatomy 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
• 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
• 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
• 125000005368 heteroarylthio group Chemical group 0.000 description 1
• 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
• 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 238000004896 high resolution mass spectrometry Methods 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 208000000122 hyperventilation Diseases 0.000 description 1
• 230000000870 hyperventilation Effects 0.000 description 1
• 201000006866 hypopharynx cancer Diseases 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000004926 indolenyl group Chemical group 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 210000001208 inner root sheath cell Anatomy 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000003601 intercostal effect Effects 0.000 description 1
• 230000004073 interleukin-2 production Effects 0.000 description 1
• 230000021995 interleukin-8 production Effects 0.000 description 1
• 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007915 intraurethral administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
• 229960002198 irbesartan Drugs 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 201000002529 islet cell tumor Diseases 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
• 125000005438 isoindazolyl group Chemical group 0.000 description 1
• 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 210000001503 joint Anatomy 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 206010023841 laryngeal neoplasm Diseases 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 239000000865 liniment Substances 0.000 description 1
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
• 229910001416 lithium ion Inorganic materials 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 230000008818 liver damage Effects 0.000 description 1
• 230000005976 liver dysfunction Effects 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 235000018977 lysine Nutrition 0.000 description 1
• 201000000564 macroglobulinemia Diseases 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 210000003584 mesangial cell Anatomy 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
• SEXTVBGVIRXDKL-UHFFFAOYSA-N methyl 3-[2-methyl-6-[1-methyl-5-[(4-nitrophenoxy)carbonyloxymethyl]triazol-4-yl]pyridin-3-yl]oxycycloheptane-1-carboxylate Chemical compound CC1=C(C=CC(=N1)C2=C(N(N=N2)C)COC(=O)OC3=CC=C(C=C3)[N+](=O)[O-])OC4CCCCC(C4)C(=O)OC SEXTVBGVIRXDKL-UHFFFAOYSA-N 0.000 description 1
• HOQUIGSAXSFJPV-UHFFFAOYSA-N methyl 3-[6-[5-(hydroxymethyl)-1-methyltriazol-4-yl]-2-methylpyridin-3-yl]oxycycloheptane-1-carboxylate Chemical compound N=1N(C(=C(N=1)C1=CC=C(OC2CC(CCCC2)C(=O)OC)C(C)=N1)CO)C HOQUIGSAXSFJPV-UHFFFAOYSA-N 0.000 description 1
• LQTUGRJOBYEGGJ-UHFFFAOYSA-N methyl 3-[6-[5-[[benzyl(methyl)carbamoyl]oxymethyl]-1-methyltriazol-4-yl]-2-methylpyridin-3-yl]oxycycloheptane-1-carboxylate Chemical compound C(C1=CC=CC=C1)N(C(=O)OCC1=C(N=NN1C)C1=CC=C(C(=N1)C)OC1CC(CCCC1)C(=O)OC)C LQTUGRJOBYEGGJ-UHFFFAOYSA-N 0.000 description 1
• 230000027939 micturition Effects 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 230000001617 migratory effect Effects 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000002297 mitogenic effect Effects 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 230000003843 mucus production Effects 0.000 description 1
• 229940124303 multikinase inhibitor Drugs 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 230000023105 myelination Effects 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 229940097496 nasal spray Drugs 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 210000003757 neuroblast Anatomy 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000003961 neuronal insult Effects 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 230000003040 nociceptive effect Effects 0.000 description 1
• 208000024696 nocturnal asthma Diseases 0.000 description 1
• 125000006574 non-aromatic ring group Chemical group 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
• 210000001331 nose Anatomy 0.000 description 1
• 238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 description 1
• 208000007892 occupational asthma Diseases 0.000 description 1
• 201000008106 ocular cancer Diseases 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 230000006712 oncogenic signaling pathway Effects 0.000 description 1
• 230000000771 oncological effect Effects 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 201000006958 oropharynx cancer Diseases 0.000 description 1
• 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000003566 oxetanyl group Chemical group 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 238000007248 oxidative elimination reaction Methods 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
• 230000008050 pain signaling Effects 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
• 201000005675 papillary conjunctivitis Diseases 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 208000029211 papillomatosis Diseases 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000003200 peritoneal cavity Anatomy 0.000 description 1
• 201000002513 peritoneal mesothelioma Diseases 0.000 description 1
• 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 230000009038 pharmacological inhibition Effects 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
• 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
• 150000002989 phenols Chemical class 0.000 description 1
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
• 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
• 208000001297 phlebitis Diseases 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
• 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
• 201000004119 pineal parenchymal tumor of intermediate differentiation Diseases 0.000 description 1
• 201000003113 pineoblastoma Diseases 0.000 description 1
• 125000004928 piperidonyl group Chemical group 0.000 description 1
• 229960005235 piperonyl butoxide Drugs 0.000 description 1
• 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
• LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
• 208000010916 pituitary tumor Diseases 0.000 description 1
• 208000010626 plasma cell neoplasm Diseases 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 231100000719 pollutant Toxicity 0.000 description 1
• 125000006684 polyhaloalkyl group Polymers 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 208000007232 portal hypertension Diseases 0.000 description 1
• 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
• 230000013155 positive regulation of cell migration Effects 0.000 description 1
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 230000036515 potency Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 208000026526 progressive weakness Diseases 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 229940127293 prostanoid Drugs 0.000 description 1
• 150000003814 prostanoids Chemical class 0.000 description 1
• 230000004224 protection Effects 0.000 description 1
• 108010062154 protein kinase C gamma Proteins 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• 230000001185 psoriatic effect Effects 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 201000003489 pulmonary alveolar proteinosis Diseases 0.000 description 1
• 230000009325 pulmonary function Effects 0.000 description 1
• 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 150000003222 pyridines Chemical class 0.000 description 1
• 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 108010062302 rac1 GTP Binding Protein Proteins 0.000 description 1
• 102000009929 raf Kinases Human genes 0.000 description 1
• 108010077182 raf Kinases Proteins 0.000 description 1
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
• 229960003401 ramipril Drugs 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000001172 regenerating effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 239000002461 renin inhibitor Substances 0.000 description 1
• 229940086526 renin-inhibitors Drugs 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 230000008458 response to injury Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 208000032253 retinal ischemia Diseases 0.000 description 1
• 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 239000003590 rho kinase inhibitor Substances 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
• 230000001932 seasonal effect Effects 0.000 description 1
• 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
• 239000002453 shampoo Substances 0.000 description 1
• 206010040560 shock Diseases 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 102000034285 signal transducing proteins Human genes 0.000 description 1
• 108091006024 signal transducing proteins Proteins 0.000 description 1
• 201000009890 sinusitis Diseases 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 102000030938 small GTPase Human genes 0.000 description 1
• 108060007624 small GTPase Proteins 0.000 description 1
• 230000016160 smooth muscle contraction Effects 0.000 description 1
• SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000006104 solid solution Substances 0.000 description 1
• 238000007614 solvation Methods 0.000 description 1
• 239000011877 solvent mixture Substances 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 206010062261 spinal cord neoplasm Diseases 0.000 description 1
• 210000003594 spinal ganglia Anatomy 0.000 description 1
• 208000005198 spinal stenosis Diseases 0.000 description 1
• 208000037959 spinal tumor Diseases 0.000 description 1
• 125000003003 spiro group Chemical group 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 210000004500 stellate cell Anatomy 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 150000003460 sulfonic acids Chemical class 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
• 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
• 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
• 125000005309 thioalkoxy group Chemical group 0.000 description 1
• 125000004001 thioalkyl group Chemical group 0.000 description 1
• 125000005403 thiohaloalkoxy group Chemical group 0.000 description 1
• BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
• RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 230000008467 tissue growth Effects 0.000 description 1
• 230000007838 tissue remodeling Effects 0.000 description 1
• 239000012443 tonicity enhancing agent Substances 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical group CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
• 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 208000009999 tuberous sclerosis Diseases 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 208000022934 urinary frequency Diseases 0.000 description 1
• 208000014001 urinary system disease Diseases 0.000 description 1
• 230000036318 urination frequency Effects 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 208000037965 uterine sarcoma Diseases 0.000 description 1
• 206010046885 vaginal cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• 230000006496 vascular abnormality Effects 0.000 description 1
• 230000006459 vascular development Effects 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 239000003038 vasopressin antagonist Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
• PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 208000009421 viral pneumonia Diseases 0.000 description 1
• 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
• 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
• 230000002747 voluntary effect Effects 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1